Advertisement
Heart, Lung and Circulation

Emerging Biomarkers in Acute Coronary Syndromes – A Pathophysiologic Perspective

Published:March 10, 2022DOI:https://doi.org/10.1016/j.hlc.2022.01.015
      Diagnosis and prognostication in acute coronary syndromes (ACS) is achieved using a combination of clinical factors and biomarkers, notably cardiac troponin and B type natriuretic peptide and its N terminal fragment NT-proBNP. However, there are numerous biomarkers that have been shown to be associated with ACS, with variable incremental utility. This brief review focusses on some promising emerging biomarkers in ACS, discussed according to pathophysiologic mechanism, as well as diagnostic and prognostic utility.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wang X.-Y.
        • Zhang F.
        • Zhang C.
        • Zheng L.-R.
        • Yang J.
        The Biomarkers for acute myocardial infarction and heart failure.
        BioMed Res Int. 2020; 2020: 1-14
        • Antman E.M.
        • Cohen M.
        • Bernink P.J.L.M.
        • McCabe C.H.
        • Horacek T.
        • Papuchis G.
        • et al.
        The TIMI Risk score for unstable angina/non–ST elevation MI: A method for prognostication and therapeutic decision making.
        JAMA. 2000; 284: 835-842
        • Boersma E.
        • Pieper K.S.
        • Steyerberg E.W.
        • Wilcox R.G.
        • Chang W.-C.
        • Lee K.L.
        • et al.
        Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients.
        Circulation. 2000; 101: 2557-2567
        • Eagle K.A.
        • Lim M.J.
        • Dabbous O.H.
        • Pieper K.S.
        • Goldberg R.J.
        • Van de Werf F.
        • et al.
        A validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month postdischarge death in an international registry.
        JAMA. 2004; 291: 2727-2733
        • Moe K.T.
        • Wong P.
        Current trends in diagnostic biomarkers of acute coronary syndrome.
        Ann Acad Med Singapore. 2010; 39: 210-215
        • Kim S.-H.
        • Weiß C.
        • Hoffmann U.
        • Borggrefe M.
        • Akin I.
        • Behnes M.
        Advantages and limitations of current biomarker research: from experimental research to clinical application.
        Curr Pharm Biotechnol. 2017; 18: 445-455
        • Aydin S.
        • Ugur K.
        • Aydin S.
        • Sahin İ.
        • Yardim M.
        Biomarkers in acute myocardial infarction: current perspectives.
        Vasc Health Risk Manag. 2019 Jan; 15: 1-10
        • Vasan R.S.
        Biomarkers of cardiovascular disease: molecular basis and practical considerations.
        Circulation. 2006; 113: 2335-2362
        • Ramasamy I.
        Biochemical markers in acute coronary syndrome.
        Clin Chim Acta. 2011; 412: 1279-1296
        • McCullough P.
        • Peacock W.
        • O’Neil B.
        • de Lemos J.
        Capturing the pathophysiology of acute coronary syndromes with circulating biomarkers.
        Rev Cardiovasc Med. 2010; 11: S3-S12
        • Libby P.
        • Tabas I.
        • Fredman G.
        • Fisher E.A.
        Inflammation and its resolution as determinants of acute coronary syndromes.
        Circ Res. 2014; 114: 1867-1879
        • Olejarz W.
        • Łacheta D.
        • Kubiak-Tomaszewska G.
        Matrix metalloproteinases as biomarkers of atherosclerotic plaque instability.
        Int J Mol Sci. 2020; 21: 3946
        • Lenglet S.
        • Mach F.
        • Montecucco F.
        Role of matrix metalloproteinase-8 in atherosclerosis.
        Mediators Inflamm. 2013; 2013: 1-6
        • Lahdentausta L.
        • Leskelä J.
        • Winkelmann A.
        • Tervahartiala T.
        • Sorsa T.
        • Pesonen E.
        • et al.
        Serum MMP-9 diagnostics, prognostics, and activation in acute coronary syndrome and its recurrence.
        J Cardiovasc Transl Res. 2018; 11: 210-220
        • Spencer T.R.
        • Sidhu M.S.
        • Bisaillon J.
        • Christopher King C.
        Novel cardiac biomarkers for emergency department evaluation of acute coronary syndrome: the recent evidence on non-troponin biomarkers and their limitations.
        Curr Emerg Hosp Med Rep. 2016; 4: 99-106
        • Pan W.
        • Yu J.
        • Shi R.
        • Yan L.
        • Yang T.
        • Li Y.
        • et al.
        Elevation of ceramide and activation of secretory acid sphingomyelinase in patients with acute coronary syndromes.
        Coron Artery Dis. 2014; 25: 230-235
        • Kook H.
        • Jang D.H.
        • Kim J.-H.
        • Cho J.-Y.
        • Joo H.J.
        • Cho S.-A.
        • et al.
        Identification of plaque ruptures using a novel discriminative model comprising biomarkers in patients with acute coronary syndrome.
        Sci Rep. 2020; 10: 20228
        • Newby A.C.
        Metalloproteinases and vulnerable atherosclerotic plaques.
        Trends Cardiovasc Med. 2007; 17: 253-258
        • Ridker P.M.
        • Luscher T.F.
        Anti-inflammatory therapies for cardiovascular disease.
        Eur Heart J. 2014; 35: 1782-1791
        • Aday A.W.
        • Ridker P.M.
        Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease.
        Front Cardiovasc Med. 2019; 6: 16
        • Riezebos R.K.
        Biochemical risk assessment and invasive strategies for acute coronary syndromes without ST-segment elevation [PhD Thesis].
        University of Amsterdam, [Amsterdam]2011
        • Liebetrau C.
        • Hoffmann J.
        • Dörr O.
        • Gaede L.
        • Blumenstein J.
        • Biermann H.
        • et al.
        Release kinetics of inflammatory biomarkers in a clinical model of acute myocardial infarction.
        Circ Res. 2015; 116: 867-875
        • Shrivastava A.K.
        • Singh H.V.
        • Raizada A.
        • Singh S.K.
        Serial measurement of lipid profile and inflammatory markers in patients with acute myocardial infarction.
        Excli J. 2015; 14: 517-526
        • Wang X.H.
        • Liu S.Q.
        • Wang Y.L.
        • Jin Y.
        Correlation of serum high-sensitivity C-reactive protein and interleukin-6 in patients with acute coronary syndrome.
        Genet Mol Res. 2014; 13: 4260-4266
        • Fanola C.L.
        • Morrow D.A.
        • Cannon C.P.
        • Jarolim P.
        • Lukas M.A.
        • Bode C.
        • et al.
        Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: Observations from the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial.
        J Am Heart Assoc. 2017; 6e005637
        • Ridker P.M.
        • Everett B.M.
        • Thuren T.
        • MacFadyen J.G.
        • Chang W.H.
        • Ballantyne C.
        • et al.
        Antiinflammatory therapy with canakinumab for atherosclerotic disease.
        N Engl J Med. 2017; 377: 1119-1131
        • Libby P.
        • Bornfeldt K.E.
        • Tall A.R.
        Atherosclerosis: successes, surprises, and future challenges.
        Circ Res. 2016; 118: 531-534
        • Mythili S.
        • Malathi N.
        Diagnostic markers of acute myocardial infarction.
        Biomed Rep. 2015; 3: 743-748
        • Mani P.
        • Puri R.
        • Schwartz G.G.
        • Nissen S.E.
        • Shao M.
        • Kastelein J.J.P.
        • et al.
        Association of initial and serial c-reactive protein levels with adverse cardiovascular events and death after acute coronary syndrome: a secondary analysis of the VISTA-16 trial.
        JAMA Cardiol. 2019; 4: 314-320
        • Kawada-Watanabe E.
        • Yamaguchi J.
        • Sekiguchi H.
        • Arashi H.
        • Ogawa H.
        • Hagiwara N.
        Targeting high-sensitivity C-reactive protein levels in acute coronary syndrome patients undergoing contemporary lipid-lowering therapy: a sub-analysis of the HIJ-PROPER trial.
        J Cardiol. 2020; 75: 500-506
        • Millard R.W.
        • Tranter M.
        Complementary, alternative, and putative nontroponin biomarkers of acute coronary syndrome: new resources for future risk assessment calculators.
        Rev Esp Cardiol. 2014; 67: 312-320
        • Kume N.
        • Mitsuoka H.
        • Hayashida K.
        • Tanaka M.
        Pentraxin 3 as a biomarker for acute coronary syndrome: Comparison with biomarkers for cardiac damage.
        J Cardiol. 2011; 58: 38-45
        • Kontny F.
        • Andersen T.
        • Ueland T.
        • Åkerblom A.
        • Lakic T.G.
        • Michelsen A.E.
        • et al.
        Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: a substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial.
        Eur Heart J Acute Cardiovasc Care. 2020; 9: 313-322
        • Ristagno G.
        • Fumagalli F.
        • Bottazzi B.
        • Mantovani A.
        • Olivari D.
        • Novelli D.
        • et al.
        Pentraxin 3 in cardiovascular disease.
        Front Immunol. 2019 17; 10: 823
        • Altay S.
        Long-term prognostic significance of pentraxin-3 in patients with acute myocardial infarction: 5-year prospective cohort study.
        Anatol J Cardiol. 2017; 17: 202-209
        • Mjelva Ø.R.
        • Pönitz V.
        • Brügger-Andersen T.
        • Grundt H.
        • Staines H.
        • Nilsen D.W.
        Long-term prognostic utility of pentraxin 3 and D-dimer as compared to high-sensitivity C-reactive protein and B-type natriuretic peptide in suspected acute coronary syndrome.
        Eur J Prev Cardiolog. 2016; 23: 1130-1140
        • Wang J.
        • Tan G.J.
        • Han L.N.
        • Bai Y.Y.
        • He M.
        • Liu H.B.
        Novel biomarkers for cardiovascular risk prediction.
        J Geriatr Cardiol. 2017; 14: 135-150
        • Hassan M.
        STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.
        Glob Cardiol Sci Pract. 2015; 2015: 6
        • White H.D.
        • Held C.
        • Stewart R.
        • Tarka E.
        • Brown R.
        • Davies R.Y.
        STABILITY Investigators, et al. Darapladib for preventing ischemic events in stable coronary heart disease.
        N Engl J Med. 2014; 370: 1702-1711
        • Wallentin L.
        • Held C.
        • Armstrong P.W.
        • Cannon C.P.
        • Davies R.Y.
        • Granger C.B.
        • et al.
        Lipoprotein-associated phospholipase A2 activity is a marker of risk but not a useful target for treatment in patients with stable coronary heart disease.
        J Am Heart Assoc. 2016; 5 (:pii:e003407)
        • Li J.
        • Wang H.
        • Tian J.
        • Chen B.
        • Du F.
        Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome.
        Medicine (Baltimore). 2018; 97: e11517
        • Madjid M.
        • Ali M.
        • Wilerson J.
        Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature.
        Tex Heart Inst J. 2010; 1: 25-39
        • Chan D.
        • Ng L.L.
        Biomarkers in acute myocardial infarction.
        BMC Med. 2010; 8: 34
        • Kaier T.E.
        • Twerenbold R.
        • Puelacher C.
        • Marjot J.
        • Imambaccus N.
        • Boeddinghaus J.
        • et al.
        Direct comparison of cardiac myosin-binding protein C with cardiac troponins for the early diagnosis of acute myocardial infarction.
        Circulation. 2017; 136: 1495-1508
        • Lyngbakken M.N.
        • Myhre P.L.
        • Røsjø H.
        • Omland T.
        Novel biomarkers of cardiovascular disease: applications in clinical practice.
        Crit Rev Clin Lab Sci. 2019; 56: 33-60
        • Kaier T.E.
        • Alaour B.
        • Marber M.
        Cardiac myosin-binding protein C—from bench to improved diagnosis of acute myocardial infarction.
        Cardiovasc Drugs Ther. 2019; 33: 221-230
        • Kaier T.E.
        • Alaour B.
        • Marber M.
        Cardiac myosin-binding protein C: how a novel biomarker could transform chest pain triage.
        Biomark Med. 2018; 12: 823-826
        • Gami B.N.
        Utility of heart-type fatty acid binding protein as a new biochemical marker for the early diagnosis of acute coronary syndrome.
        J Clin Diagn Res. 2015; 9: BC22-BC24
        • Ye X.
        • He Y.
        • Wang S.
        • Wong G.T.
        • Irwin M.G.
        • Xia Z.
        Heart-type fatty acid binding protein (H-FABP) as a biomarker for acute myocardial injury and long-term post-ischemic prognosis.
        Acta Pharmacol Sin. 2018; 39: 1155-1163
        • Jones J.D.
        • Chew P.G.
        • Dobson R.
        • Wootton A.
        • Ashrafi R.
        • Khand A.
        The prognostic value of heart type fatty acid binding protein in patients with suspected acute coronary syndrome: a systematic review.
        Curr Cardiol Rev. 2017; 13: 189-198
        • Bivona G.
        • Agnello L.
        • Bellia C.
        • Lo Sasso B.
        • Ciaccio M.
        Diagnostic and prognostic value of H-FABP in acute coronary syndrome: still evidence to bring.
        Clin Biochem. 2018; 58: 1-4
        • Agnello L.
        • Bivona G.
        • Novo G.
        • Scazzone C.
        • Muratore R.
        • Levantino P.
        • et al.
        Heart-type fatty acid binding protein is a sensitive biomarker for early AMI detection in troponin negative patients: a pilot study.
        Scand J Clin Lab Invest. 2017; 77: 428-432
        • Dupuy A.M.
        • Cristol J.P.
        • Kuster N.
        • Reynier R.
        • Lefebvre S.
        • Badiou S.
        • et al.
        Performances of the heart fatty acid protein assay for the rapid diagnosis of acute myocardial infarction in ED patients.
        Am J Emerg Med. 2015; 33: 326-330
        • Lindholm D.
        • James S.K.
        • Gabrysch K.
        • Storey R.F.
        • Himmelmann A.
        • Cannon C.P.
        • et al.
        Association of multiple biomarkers with risk of all-cause and cause-specific mortality after acute coronary syndromes: a secondary analysis of the PLATO biomarker study.
        JAMA Cardiol. 2018; 3: 1160
        • Zhang S.
        • Dai D.
        • Wang X.
        • Zhu H.
        • Jin H.
        • Zhao R.
        • et al.
        Growth differentiation factor–15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis.
        BMC Cardiovasc Disord. 2016; 16: 82
        • Hagström E.
        • James S.K.
        • Bertilsson M.
        • Becker R.C.
        • Himmelmann A.
        • Husted S.
        • et al.
        Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.
        Eur Heart J. 2016; 37: 1325-1333
        • Lindholm D.
        • Hagström E.
        • James S.K.
        • Becker R.C.
        • Cannon C.P.
        • Himmelmann A.
        • et al.
        Growth differentiation factor 15 at 1 month after an acute coronary syndrome is associated with increased risk of major bleeding.
        J Am Heart Assoc. 2017; 6e005580
        • de Carvalho L.P.
        • Tan S.H.
        • Ow G.-S.
        • Tang Z.
        • Ching J.
        • Kovalik J.-P.
        • et al.
        Plasma ceramides as prognostic biomarkers and their arterial and myocardial tissue correlates in acute myocardial infarction.
        JACC Basic Transl Sci. 2018; 3: 163-175
        • Meeusen J.W.
        • Donato L.J.
        • Jaffe A.S.
        Lipid biomarkers for risk assessment in acute coronary syndromes.
        Curr Cardiol Rep. 2017; 19: 48
        • Yao K.
        • Wang Y.
        • Xu D.
        • Liu X.
        • Shen C.
        • Hu W.
        • et al.
        Effect of combined testing of ceramides with high-sensitive troponin T on the detection of acute coronary syndrome in patients with chest pain in China: a prospective observational study.
        BMJ Open. 2019; 9e028211
        • Mantovani A.
        • Dugo C.
        Ceramides and risk of major adverse cardiovascular events: a meta-analysis of longitudinal studies.
        J Clin Lipidol. 2020; 14: 176-185
        • Laaksonen R.
        • Ekroos K.
        • Sysi-Aho M.
        • Hilvo M.
        • Vihervaara T.
        • Kauhanen D.
        • et al.
        Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol.
        Eur Heart J. 2016; 37: 1967-1976
        • Anroedh S.
        • Hilvo M.
        • Akkerhuis K.M.
        • Kauhanen D.
        • Koistinen K.
        • Oemrawsingh R.
        • et al.
        Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients.
        J Lipid Res. 2018; 59: 1729-1737
        • Hilvo M.
        • Meikle P.J.
        • Pedersen E.R.
        • Tell G.S.
        • Dhar I.
        • Brenner H.
        • et al.
        Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients.
        Eur Heart J. 2020; 41: 371-389
        • Wang D.D.
        • Toledo E.
        • Hruby A.
        • Rosner B.A.
        • Willett W.C.
        • Sun Q.
        • et al.
        Plasma ceramides, mediterranean diet, and incident cardiovascular disease in the PREDIMED Trial (prevention wtih mediterranean diet).
        Circulation. 2017; 135: 2028-2040
        • Trøseid M.
        Gut microbiota and acute coronary syndromes: ready for use in the emergency room?.
        Eur Heart J. 2017; 38: 825-827
        • Suzuki T.
        • Heaney L.M.
        • Jones D.J.L.
        • Ng L.L.
        Trimethylamine N-oxide and risk stratification after acute myocardial infarction.
        Clin Chem. 2017; 63: 420-428
        • Li X.S.
        • Obeid S.
        • Klingenberg R.
        • Gencer B.
        • Mach F.
        • Räber L.
        • et al.
        Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors.
        Eur Heart J. 2017; 38: 814-824
        • Tan Y.
        • Sheng Z.
        • Zhou P.
        • Liu C.
        • Zhao H.
        • Song L.
        • et al.
        Plasma trimethylamine N-oxide as a novel biomarker for plaque rupture in patients with ST-segment–elevation myocardial infarction.
        Circ Cardiovasc Interv. 2019; 12e007281
        • Roberts A.B.
        • Gu X.
        • Buffa J.A.
        • Hurd A.G.
        • Wang Z.
        • Zhu W.
        • et al.
        Development of a gut microbe–targeted nonlethal therapeutic to inhibit thrombosis potential.
        Nat Med. 2018; 24: 1407-1417